89bio, inc. announces proposed underwritten public offering of common stock and pre-funded warrants

San francisco, nov. 12, 2024 (globe newswire) -- 89bio, inc. (“89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. in addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $15 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. the proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. all of the securities to be sold in the offering are being offered by 89bio.
ETNB Ratings Summary
ETNB Quant Ranking